psilocybin

Product

Last mentioned: Mar 6, 2026

Timeline

2024
Phase 3 Trials

Large-scale multi-site trials aim to provide definitive data for regulatory approval.
2022
SAP Expansion

Canada amends the Special Access Program to include restricted psychedelic substances.
2020
Regulatory Shift

Health Canada begins granting Section 56 exemptions for terminally ill patients.
2016
Foundational Research

Johns Hopkins and NYU publish landmark studies on psilocybin for cancer-related distress.

Stories mentioning psilocybin 1

Psilocybin Shows Clinical Promise in Easing End-of-Life Existential Distress

Emerging clinical research indicates that psilocybin-assisted therapy can significantly alleviate existential dread and depression in terminally ill patients. This development marks a potential paradigm shift in palliative care, moving beyond physical pain management to address deep-seated psychological trauma.

Mar 6, 2026 2 sources